H.C. Wainwright raised the price target for the Cidara Therapeutics Inc. (NASDAQ:CDTX) stock to “a Buy”. The rating was released on December 03, 2021, according to finviz. The research report from Aegis Capital has initiated the stock to Buy, with a price target set at $9. The stock was upgraded by Wedbush, who disclosed in a research note on September 04, 2019, from Neutral to Outperform and set the price objective to $4. In their research brief published July 26, 2018, Citigroup analysts initiated the Cidara Therapeutics Inc. stock to Buy with a price target of $8.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Cidara Therapeutics Inc. (NASDAQ:CDTX) dipped -5.45% to close Wednesday’s market session at $0.66, lower as compared to yesterday’s close. The stock price fluctuated between $0.66 and $0.7323 throughout the trading session with the volume trading being 445506 shares, which represented a significant variation when compared to the three months average volume of 235.90K shares. The firm’s stock price fluctuated 8.10% within the last five trades and 14.62% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 48.13% in the last 6 months and -5.03% was subtracted to its value over the previous 3 months. CDTX stock is trading at a margin of 10.75%, 6.64% and -0.26% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, CDTX deals in the Healthcare domain. The stock is trading -61.12 percent below its 52-week high and 66.20 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -41.8. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Cidara Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -56.80 percent and the profit margin is -56.60 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $47.93 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 0.78 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 5.11, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.20 percent of Cidara Therapeutics Inc. shares are owned by insiders, and 39.60 percent are held by financial institutions. Shah Preetam, the CFO & CBO at Cidara Therapeutics Inc. (CDTX) has sold 15,642 shares of firm on Sep 19 at a price of $0.77 against the total amount of $12035.0. In another inside trade, Sandison Taylor, Chief Medical Officer of Cidara Therapeutics Inc. (NASDAQ:CDTX) sold 18,478 shares of the firm on Sep 12 for a total worth of $12656.0 at a price of $0.68. An inside trade which took place on Sep 12, CHIEF SCIENTIFIC OFFICER of Cidara Therapeutics Inc. Tari Leslie sold 18,159 shares of firm against total price of $12437.0 at the cost of $0.68 per share.